4.7 Article

Adenovirus Vectors Expressing Eight Multiplex Guide RNAs of CRISPR/Cas9 Efficiently Disrupted Diverse Hepatitis B Virus Gene Derived from Heterogeneous Patient

Journal

Publisher

MDPI
DOI: 10.3390/ijms221910570

Keywords

CRISPR/Cas9; genome editing; adenovirus vector; multiplex guide RNAs; hepatitis B virus (HBV); hepatocellular carcinoma; gene therapy

Funding

  1. Program on the Innovative Development and the Application of New Drugs for Hepatitis B from Japan Agency for Medical Research and Development (AMED) [JP21fk0310107]
  2. Research Program on Emerging and Reemerging Infectious Diseases from Japan Agency for Medical Research and Development (AMED) [JP21fk0108106, JP20fk0108267, JP20fk0108281]
  3. Translational Research Program, Strategic Promotion for Practical Application of Innovative Medical Technology, TR-SPRINT from Japan Agency for Medical Research and Development (AMED) [A114]
  4. JSPS KAKENHI [JP19K0647]

Ask authors/readers for more resources

Hepatitis B virus infects over 240 million people globally, leading to chronic diseases such as cirrhosis and liver cancer. The diversity of HBV genome sequences poses a challenge in developing genome editing therapies. An adenovirus vector carrying multiple gRNA expression units offers a potential solution to target diverse HBV genomes for effective editing.
Hepatitis B virus (HBV) chronically infects more than 240 million people worldwide, causing chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Genome editing using CRISPR/Cas9 could provide new therapies because it can directly disrupt HBV genomes. However, because HBV genome sequences are highly diverse, the identical target sequence of guide RNA (gRNA), 20 nucleotides in length, is not necessarily present intact in the target HBV DNA in heterogeneous patients. Consequently, possible genome-editing drugs would be effective only for limited numbers of patients. Here, we show that an adenovirus vector (AdV) bearing eight multiplex gRNA expression units could be constructed in one step and amplified to a level sufficient for in vivo study with lack of deletion. Using this AdV, HBV X gene integrated in HepG2 cell chromosome derived from a heterogeneous patient was cleaved at multiple sites and disrupted. Indeed, four targets out of eight could not be cleaved due to sequence mismatches, but the remaining four targets were cleaved, producing irreversible deletions. Accordingly, the diverse X gene was disrupted at more than 90% efficiency. AdV containing eight multiplex gRNA units not only offers multiple knockouts of genes, but could also solve the problems of heterogeneous targets and escape mutants in genome-editing therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available